SECRETIN SYNTHETIC HUMAN - Generic Drug Details

What are the generic drug sources for secretin synthetic human and what is the scope of patent protection?

Secretin synthetic human is the generic ingredient in one branded drug marketed by Chirhoclin and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for SECRETIN SYNTHETIC HUMAN

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	12
Clinical Trials:	10
DailyMed Link:	SECRETIN SYNTHETIC HUMAN at DailyMed

Recent Clinical Trials for SECRETIN SYNTHETIC HUMAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
ChiRhoClin, Inc.	Phase 2
Dartmouth-Hitchcock Medical Center	Phase 2
Massachusetts General Hospital	Phase 1

See all SECRETIN SYNTHETIC HUMAN clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for SECRETIN SYNTHETIC HUMAN

V04CK	Tests for pancreatic function
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for SECRETIN SYNTHETIC HUMAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-002	Jun 21, 2007		RX	Yes	No
Chirhoclin	CHIRHOSTIM	secretin synthetic human	FOR SOLUTION;INTRAVENOUS	021256-001	Apr 9, 2004		RX	Yes	Yes

Secretin Synthetic Human Market Dynamics, Patent Position, and Financial Trajectory

Last updated: September 9, 2026

Secretin synthetic human is a mature, highly specialized diagnostic drug rather than a mass-market therapeutic. The principal U.S. product is ChiRhoStim, an injectable synthetic human secretin marketed by ChiRhoClin for pancreatic function testing and gastrin stimulation. Its commercial value depends on procedure volume at gastroenterology centers, availability of specialized testing, and the limited number of qualified suppliers.

The product has no publicly disclosed standalone revenue, and ChiRhoClin is privately held. The financial trajectory is therefore best assessed through market structure, regulatory barriers, procedural demand, manufacturing complexity, and substitution risk rather than reported sales.

What is secretin synthetic human used for?

Secretin synthetic human is an injectable peptide hormone used as a diagnostic aid. It stimulates pancreatic secretion of bicarbonate and digestive enzymes and can stimulate gastrin release in patients being evaluated for gastrinoma.

Attribute	Secretin synthetic human
Active ingredient	Synthetic human secretin
Primary U.S. brand	ChiRhoStim
Sponsor or marketer	ChiRhoClin, Inc.
FDA pathway	New drug application
NDA	NDA 021044
Dosage form	Injectable solution or lyophilized product for reconstitution, depending on presentation
Main use	Pancreatic function testing and gastrin stimulation
Therapeutic category	Diagnostic gastrointestinal agent
Typical users	Gastroenterologists, academic hospitals, pancreatic disease centers
Commercial market	Niche, procedure-driven, specialty pharmaceutical

The product is not used for chronic treatment. It is administered in connection with a diagnostic procedure, which limits prescription frequency but can support recurring institutional demand.

FDA labeling identifies pancreatic function testing and gastrin stimulation as the principal uses. The label also describes adverse reactions including nausea, abdominal discomfort, flushing, vomiting, and cardiovascular effects associated with administration of secretin [1].

What is the FDA status of secretin synthetic human?

ChiRhoStim received FDA approval under NDA 021044 in 2004. The product is regulated as a prescription diagnostic drug rather than as a medical device or biologic [1].

Its FDA status has several commercial implications:

1. The product is an approved drug with established labeling.
2. The market is not dependent solely on compounding or off-label supply.
3. Hospitals and diagnostic centers can purchase an FDA-approved product for labeled uses.
4. The market remains small because the drug is used only during selected gastrointestinal diagnostic procedures.

The FDA approval does not create a large chronic-use market. Demand is linked to specialist testing for pancreatic exocrine insufficiency, chronic pancreatitis, unexplained pancreatic disease, and suspected gastrinoma.

When does secretin synthetic human lose exclusivity?

The original U.S. regulatory exclusivity period has expired. An approval in 2004 would not support current new-chemical-entity exclusivity, and any applicable five-year exclusivity would have ended no later than 2009. Any seven-year orphan-drug exclusivity, if granted, would also have expired long ago.

Protection type	Relevant period	Current commercial effect
FDA approval	2004	Remains the foundation for marketing
Five-year new-chemical-entity exclusivity	Expected to expire by 2009 if applicable	Expired
Seven-year orphan exclusivity	Would have expired by 2011 if applicable	Expired
Patent exclusivity	No current patent term is central to the product’s commercial position in the public FDA record	Limited or expired
Regulatory exclusivity today	None material identified	Market depends on approval, supply, and demand

The absence of active regulatory exclusivity does not guarantee immediate generic competition. A small diagnostic market may not justify the cost of developing, validating, manufacturing, and commercializing a competing injectable peptide.

What patents protect secretin synthetic human?

The commercial protection for secretin synthetic human appears to be weaker than the protection for recently launched specialty drugs. Secretin is an established peptide with a known sequence and long history of clinical use. Core composition-of-matter patents would generally be expected to be expired or commercially irrelevant.

The remaining competitive barriers are more likely to involve:

• Manufacturing controls for a synthetic peptide.
• Sterility and injectable-product validation.
• Stability and reconstitution performance.
• Analytical characterization.
• Process reproducibility.
• FDA approval requirements.
• Hospital procurement relationships.
• Small market economics.

No active patent term is the primary explanation for the product’s market position. The relevant protection is operational and regulatory. A new entrant would need to demonstrate pharmaceutical equivalence or otherwise satisfy FDA requirements, establish reliable supply, and gain access to a narrow specialist market.

What formulations are protected by secretin patents?

Publicly available product information does not establish a commercially meaningful current patent estate covering a differentiated secretin formulation. The product’s value is based on the approved injectable presentation and its diagnostic labeling, not on an extended-release, device-enabled, or reformulated delivery system.

Potential formulation barriers include:

• Peptide degradation during storage.
• Container-closure compatibility.
• Sterile manufacturing.
• Reconstitution time.
• Dose uniformity.
• Product stability after preparation.

These attributes can increase development cost without creating durable patent exclusivity.

How many patents cover secretin synthetic human?

The practical answer is that no significant active patent portfolio is publicly associated with the current U.S. commercial product. The FDA Orange Book remains the relevant source for patents listed with an approved drug product. The commercial profile of ChiRhoStim does not resemble a product protected by a large, actively litigated Orange Book estate [2].

This creates a low formal patent barrier but does not eliminate market friction. Secretin is an example of a product where supply qualification, low demand, and manufacturing know-how may matter more than patent count.

What is the Orange Book status of secretin synthetic human?

The Orange Book framework applies to approved drug products and provides information on listed patents and exclusivity. For secretin synthetic human, the important commercial conclusion is that current market access is not primarily controlled by an unexpired Orange Book patent.

The product’s Orange Book position should be read together with:

• NDA 021044 approval history.
• Current FDA labeling.
• Any active abbreviated new drug application.
• Drug shortage and discontinuation records.
• National Drug Code listing and manufacturer status.

A lack of active listed patents lowers the legal barrier to an ANDA challenge. It does not establish that a generic sponsor has filed an ANDA or that FDA approval is imminent.

Are there Paragraph IV challenges or generic competitors?

Secretin synthetic human is legally exposed to generic competition because its principal exclusivity periods have expired. The commercial risk is moderate in legal terms but lower in economic terms because the market is small and technically demanding.

No material Paragraph IV litigation or settlement involving ChiRhoStim is established by the FDA sources cited here. There is also no evidence in the public product profile of a broad wave of approved generic secretin products.

A generic entrant would likely face:

Issue	Impact on entrant
Small procedure-linked market	Limits expected return on development
Injectable peptide manufacturing	Raises technical and quality costs
Hospital purchasing	Requires formulary and contract access
Limited prescriber base	Restricts commercial scale
Diagnostic substitution	Reduces market certainty
Supply reliability	Can determine adoption more than price
FDA comparability requirements	Adds development and regulatory work

A successful ANDA entrant could still gain share rapidly if it offers lower pricing and reliable availability. The incumbent’s primary defense would be supply continuity, customer relationships, and execution rather than patent litigation.

Is secretin synthetic human exposed to biosimilar competition?

Secretin synthetic human is not a conventional biologic-biosimilar opportunity. It is a chemically synthesized peptide drug and would generally be evaluated through a small-molecule or drug-product approval framework rather than the 351(k) biosimilar pathway used for licensed biologics.

The principal competitive route is therefore a generic or other abbreviated drug application, subject to the applicable FDA requirements. Biosimilar risk is not the relevant competitive category.

This distinction matters for investors and licensors. Secretin does not have the market dynamics of insulin analogs, monoclonal antibodies, or other biologic products where biosimilar interchangeability and reference-product exclusivity drive competition.

What market factors determine secretin synthetic human demand?

Demand is determined by diagnostic practice rather than disease prevalence alone.

Pancreatic function testing

Direct pancreatic function testing can use secretin stimulation to assess exocrine pancreatic function. It is most relevant when clinicians need information beyond routine blood tests, imaging, or indirect stool-based assays.

Potential demand drivers include:

• Greater recognition of exocrine pancreatic insufficiency.
• More diagnosis of chronic pancreatitis.
• Growth in specialized pancreatic disease programs.
• Use of secretin-enhanced imaging and functional evaluation.
• Referral concentration at academic and tertiary-care hospitals.

Substitution by other diagnostic methods

Secretin competes with several alternatives:

Alternative	Competitive effect
Fecal elastase testing	Lower-cost, noninvasive, widely available
Direct pancreatic function testing without commercial secretin	May be used in selected centers
Endoscopic pancreatic function testing	Provides procedure-based assessment
Secretin-enhanced MRCP	Uses secretin to improve ductal and functional imaging
Standard CT or MRI	Often used before invasive testing
Empiric pancreatic enzyme therapy	Can reduce demand for definitive functional testing

Secretin-enhanced MRCP may support demand for secretin in some institutions, but imaging utilization varies by reimbursement, local expertise, and equipment access. The product therefore benefits from specialist adoption while remaining vulnerable to nonsecretin diagnostic pathways.

How strong is the commercial position of ChiRhoStim?

The product has a defensible niche but limited growth potential.

Strengths

• FDA-approved diagnostic labeling.
• Established use in specialist gastroenterology.
• Limited direct competition.
• High switching friction when hospitals value supply continuity.
• Technical complexity associated with sterile peptide manufacturing.
• Low likelihood of broad price-driven substitution in urgent diagnostic settings.

Weaknesses

• No chronic-treatment demand.
• Small addressable procedure base.
• No meaningful current patent moat.
• Dependence on a private company with limited public financial disclosure.
• Exposure to hospital budget pressure.
• Substitution by noninvasive or imaging-based tests.
• Potential vulnerability to manufacturing interruptions.

The product’s position is stronger operationally than legally. A competitor may find it difficult to justify entry, but an entrant that solves supply or pricing problems could gain institutional accounts without overcoming a significant patent wall.

What is the financial trajectory for secretin synthetic human?

No publicly reported standalone revenue, operating margin, or unit-volume data are available for ChiRhoStim. ChiRhoClin is privately held, so the product cannot be valued from public-company segment reporting.

The most supportable financial assessment is:

Period	Likely financial profile
Launch and early adoption	Gradual specialist uptake after FDA approval
Mature period	Stable niche revenue tied to diagnostic volume
Current period	Low-scale, defensively maintained revenue with limited organic expansion
Downside case	Decline from substitution, hospital consolidation, or supply disruption
Upside case	Incremental growth from pancreatic centers and secretin-enhanced imaging
Generic-entry case	Price pressure and potential share loss if an approved competitor launches

Revenue can be modeled as:

Annual revenue = diagnostic procedures x secretin utilization rate x net price per treatment

The main variables are procedure volume, institutional adoption, dosing practices, and net realized price. Price increases alone are unlikely to produce substantial long-term growth because the market is small and hospitals can reassess test economics.

The likely financial trajectory is mature and niche, with stability dependent on reliable supply. It is not a high-growth specialty pharmaceutical asset unless the sponsor expands use into broader pancreatic imaging or obtains additional diagnostic indications.

What manufacturing and intellectual-property barriers affect the market?

Manufacturing is a more important barrier than patent protection.

Secretin is a peptide that requires controlled synthesis, purification, characterization, sterile processing, and stability testing. Commercial reliability depends on the ability to maintain consistent potency and impurity profiles across batches.

Key manufacturing risks include:

• Raw-material qualification.
• Peptide synthesis yield.
• Purification and impurity control.
• Sterile filling.
• Lyophilization or solution stability.
• Shipping and storage conditions.
• Batch-release testing.
• Backup manufacturing capacity.

These requirements can discourage generic entry even when the legal patent environment is open. They can also create disproportionate commercial damage from a single prolonged supply interruption because hospitals may switch permanently to alternative diagnostic methods.

What litigation and settlement risks affect secretin synthetic human?

The product does not appear to have a major current litigation profile. The primary legal risks are more likely to arise from:

• FDA manufacturing observations.
• Product quality or recall events.
• Supply-contract disputes.
• Labeling or promotional claims.
• A future ANDA Paragraph IV challenge.
• Patent disputes over a new formulation or diagnostic method.

A future formulation patent could create a narrower dispute, but such a patent would protect only the claimed formulation or use. It would not necessarily block an equivalent conventional secretin product.

No material settlement agreement is identified in the cited public FDA materials. The absence of a settlement history reduces evidence of active Hatch-Waxman conflict but does not prevent future generic litigation.

How does secretin synthetic human compare with larger specialty drugs?

Dimension	Secretin synthetic human	Large specialty drug
Use	Diagnostic procedure	Chronic or acute treatment
Patient volume	Low	Moderate to high
Revenue visibility	Limited	Usually reported
Patent dependence	Low	Often high
Regulatory exclusivity	Expired	May remain active
Generic risk	Economically constrained	Often substantial
Biosimilar risk	Not applicable	Relevant for biologics
Pricing power	Moderate in niche settings	Can be high
Growth driver	Procedure adoption	Disease prevalence and treatment share
Manufacturing risk	High relative to market size	Managed at larger scale

Secretin synthetic human is better viewed as a specialized diagnostic supply business than as a conventional growth pharmaceutical.

What generic launch scenarios exist?

No generic launch

The incumbent retains the market if development economics remain unattractive. Revenue remains tied to diagnostic volumes and supply reliability.

Single generic launch

A single approved generic could reduce net pricing and pressure the incumbent’s institutional contracts. Share erosion would depend on whether hospitals prioritize lower cost or established supply.

Multiple generic launches

A multi-entrant market would create meaningful price erosion. This scenario is less likely unless a sponsor can use an existing peptide manufacturing platform and distribute through an established hospital-sales network.

Supply-disruption launch

A competitor could gain rapid adoption if the incumbent experiences a shortage. In a small market, temporary supply failure can accelerate permanent account switching.

What is the geographic coverage of secretin synthetic human?

The strongest commercial position is in the United States, where ChiRhoStim has an FDA-approved product and established specialist use. International availability is more fragmented and depends on local marketing authorization, importer arrangements, reimbursement, and hospital practice.

Geographic expansion is constrained by:

• Small procedure volumes in individual countries.
• Separate regulatory filings.
• Peptide manufacturing and cold-chain requirements.
• Low awareness outside specialist centers.
• Variable reimbursement for pancreatic function testing.
• Availability of alternative imaging and stool-based diagnostics.

The most attractive international markets are countries with concentrated tertiary-care gastroenterology networks and established secretin-enhanced imaging programs. Broad primary-care expansion is unlikely.

Key Takeaways

• Secretin synthetic human is a mature diagnostic peptide, primarily represented in the U.S. by ChiRhoStim.
• FDA approval was granted under NDA 021044 in 2004.
• Core regulatory exclusivity has expired, and the product does not appear to rely on an active Orange Book patent estate.
• The main competitive barriers are sterile peptide manufacturing, quality control, supply reliability, and specialist distribution.
• Biosimilar competition is not the relevant risk; generic competition is.
• No standalone public revenue data are available for ChiRhoStim or ChiRhoClin.
• Financial performance is likely stable but limited by a small, procedure-driven market.
• Growth depends on pancreatic diagnostic adoption and secretin-enhanced imaging rather than chronic treatment expansion.
• The greatest downside risks are diagnostic substitution, manufacturing interruption, and a reliable low-cost generic entrant.
• The product has niche commercial defensibility but limited evidence of high-growth potential.

FAQs About Secretin Synthetic Human

Is secretin synthetic human still FDA approved?

Yes. The principal U.S. product, ChiRhoStim, was approved under NDA 021044 and remains associated with diagnostic use for pancreatic secretion and gastrin stimulation [1].

Is secretin synthetic human a biologic?

No. It is a chemically synthesized peptide drug, not a conventional biologic subject to the biosimilar pathway under section 351(k) of the Public Health Service Act.

Does secretin synthetic human have an active patent?

No material active patent protection is central to the current commercial position identified in the public FDA record. The market is protected more by manufacturing and supply barriers than by patent exclusivity.

Can secretin synthetic human be replaced by fecal elastase?

In some clinical settings, yes. Fecal elastase is noninvasive and easier to deploy, although it does not provide the same direct stimulation-based assessment as secretin testing.

Is secretin synthetic human a high-growth pharmaceutical market?

No. It is a small specialty diagnostic market. Growth is more likely to be incremental and procedure-driven than comparable with chronic-care or specialty biologic markets.

References

1. U.S. Food and Drug Administration. (2004). ChiRhoStim (secretin) for injection: Prescribing information and approval record, NDA 021044. FDA Drugs@FDA.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs database. FDA.